Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
The U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc.’s emergency authorization request for the company’s COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc.’s vaccine for those aged 6 months through 4 years.
U.S. FDA authorizes Pfizer’s COVID booster shot for young children
BNT162b2 (Pfizer and BioNTech), Children 5-11 Years, Coronavirus Disease (COVID-19) Pandemic, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccinations, COVID-19 Vaccines, Emergency Use Authorization (EUA), FDA, Pandemics, Pediatric, Pediatric Vaccines, Pfizer, Therapeutics, VaccinationsThe U.S. Food and Drug Administration on May 17 authorized the use of a booster shot of Pfizer and BioNTech’s COVID-19 vaccine for children aged 5 to 11, making everyone in the United States over the age of 5 eligible for a third shot.
Moderna files for U.S. authorization of COVID shot for kids under 6
Children, Coronavirus Vaccines, COVID-19 Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Omicron BA.2, Pediatric, Pediatric Patients, Pediatric Vaccines, Pediatrics, Pediatrics, TherapeuticsModerna Inc. asked U.S. regulators to authorize the company’s COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.
Child vaccination rates in the United States fell during the COVID-19 pandemic as many children skipped doctors appointments and states eased vaccine requirements during remote learning, according to a government study released on April 21.